ondasdechoque.org
PT-BR

Knee osteoarthritis, Kellgren–Lawrence grade II–III · Randomized trial · 2013

Does shockwave help knee osteoarthritis pain?

In this trial, four weekly shockwave sessions brought pain on movement down from about 7.6 to 3.8 out of 10 by 12 weeks. With placebo, it fell from about 7.6 to 6.4. Knee function scores also improved more with shockwave.

Helped more than placebo
adults with grade II–III knee osteoarthritis
70
sessions, one a week
4
weeks of follow-up
12

Good to know: The report has some inconsistencies.

Zhao Z, Jing R, Shi Z, et al. The Journal of Surgical Research, 2013 · Read the paper ↗

How this study worked

Shockwave34 peoplePlacebo36 peopleShockwaveSham
People were assigned by lot. One group had a sham: the same-looking treatment without the active waves. Each dot is one person.

What happened

Knee pain on movement

0–10 pain scale · start and after 12 weeks

StartAfter 12 weeks

Pain on movement fell from about 7.6 to 3.8 out of 10 with shockwave and from about 7.6 to 6.4 with placebo.
Show the numbers
GroupPeopleStartAfter 12 weeks
Shockwave347.563.83
Placebo367.556.41

The treatment

Shockwave

Shockwave, once a week for 4 weeks

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
4, one a week
Pulses
4,000 per session
Strength
0.25mJ/mm² · 6 per second
Numbing
Not mentioned
Device
Swiss DolorClast
Everyone also got
No other treatments; low activity advised for 48 hours after each session

Compared with: Placebo: the same device and procedure at zero energy

Settings are what each study used, not a prescription.

Who took part

70 adults aged 45 or older with grade II–III knee osteoarthritis and knee pain for at least 3 months, from two rheumatology clinics.

Shockwave34 people
Placebo36 people

Side effects

Brief skin redness and swelling lasting a few days, mentioned without counts.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults aged 45 or older from two rheumatology clinics with symptomatic primary knee osteoarthritis by American College of Rheumatology criteria, knee pain for the previous 3 months and Kellgren–Lawrence grade II or III; one target knee per person. Mean ages 61.8 (placebo) and 59.9 years (shockwave); 25 of 36 and 20 of 34 were women; 26 per group had grade II. Baseline pain on walking was 7.6 on a 10-cm VAS in both groups. Spinal stenosis, neurological disease, inflammatory or metabolic arthritis, and knee surgery or injection in the previous 6 months were exclusions.

Shockwave therapy34randomized

People, one target knee each. 34 in the intent-to-treat analysis; 30 completed 12 weeks (2 lost to follow-up or work commitments, 2 lack of efficacy). Imputation method not described.

Placebo at 0 mJ/mm²36randomized

People, one target knee each. 36 in the intent-to-treat analysis; 31 completed 12 weeks (2 increased pain and analgesic use, labelled adverse events in Figure 1; 3 lack of efficacy). Imputation method not described.

10-cm visual analog scale (VAS), primary outcome1 reported outcome
01
12 weeks

Pain on movement

10-cm visual analog scale (VAS), primary outcome cm (0–10)

BaselineFollow-up
Shockwave therapy
3.83
Placebo at 0 mJ/mm²
6.41
010 cm (0–10)
means
GroupnBaselineFollow-up
Shockwave therapy347.563.83
Placebo at 0 mJ/mm²367.556.41

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.01

Shockwave versus placebo, decrease in VAS at each period, intent-to-treat

Independent-samples t test or Mann–Whitney test on change from baseline (not specified)

Mean VAS fell 3.73 points with shockwaves (7.56 to 3.83) and 1.14 points with placebo (7.55 to 6.41); both within-group changes P<0.01. The between-group difference in decrease was reported as P<0.01 without an interval.

Analysis details and source

Means from the Results text in the intent-to-treat population; no SD or confidence interval given at 12 weeks. Table 1 reports baseline 'pain on walking' as 7.6 ± 1.1 (placebo) and 7.6 ± 1.3 (shockwave), whereas the primary outcome is called pain on movement. The Discussion's statement that baseline pain was better with shockwaves contradicts these values.

10-cm visual analog scale (VAS)1 reported outcome
02
1 and 4 weeks

Pain on movement, early visits

10-cm visual analog scale (VAS) cm (0–10)

The paper reports a greater VAS decrease with shockwaves than with placebo at each assessment (P<0.01). Values at 1 and 4 weeks are shown only as plotted mean changes in Figure 2.

Analysis details and source

Figure values were not extracted as numbers; no table reports them.

Lequesne index2 reported outcomes
03
Change from baseline to 12 weeks, intent-to-treat

Lequesne index

Lequesne index Points

means
GroupnBaselineReported change
Shockwave therapy34—-4.1 [CI -4.9; -3.3]
Placebo at 0 mJ/mm²36—-2 [CI -2.9; -1]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-2.1CI 95% -3.4 to -0.9p <0.01

Shockwave minus placebo

No adjustment reported

-3.8Equal results 00.4

Disability on the Lequesne index fell more with shockwaves than with placebo over 12 weeks: difference −2.1 points (95% CI −3.4 to −0.9).

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). The intent-to-treat columns use 36 and 34 although nine patients withdrew; imputation is not described. Baseline 10.2 ± 2.3 (shockwave) and 10.1 ± 2.4 (placebo); maximum score 24.

04
Change from baseline to 12 weeks, per-protocol completers

Lequesne index, completers

Lequesne index Points

means
GroupnBaselineReported change
Shockwave therapy30—-4.6 [CI -5.4; -3.9]
Placebo at 0 mJ/mm²31—-2.3 [CI -3.4; -1.2]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-2.3CI 95% -3.6 to -1.1p <0.01

Shockwave minus placebo

No adjustment reported

-4Equal results 00.4

Among completers the Lequesne difference was −2.3 points (95% CI −3.6 to −1.1), favoring shockwaves.

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). Completers only (31 placebo, 30 shockwave); exclusion of withdrawals can bias the comparison.

WOMAC total2 reported outcomes
05
Change from baseline to 12 weeks, intent-to-treat

WOMAC total

WOMAC total Points

means
GroupnBaselineReported change
Shockwave therapy34—-19.1 [CI -22.7; -15.6]
Placebo at 0 mJ/mm²36—-8.5 [CI -12.4; -4.6]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-10.6CI 95% -15.8 to -5.4p <0.01

Shockwave minus placebo

No adjustment reported

-17.7Equal results 01.9

WOMAC total fell more with shockwaves than with placebo: difference −10.6 points (95% CI −15.8 to −5.4) on a 0–96 scale.

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). The intent-to-treat columns use 36 and 34 although nine patients withdrew; imputation is not described. Baseline 36.4 ± 10.3 (shockwave) and 32.8 ± 10.9 (placebo).

06
Change from baseline to 12 weeks, per-protocol completers

WOMAC total, completers

WOMAC total Points

means
GroupnBaselineReported change
Shockwave therapy30—-21.5 [CI -24.4; -18.5]
Placebo at 0 mJ/mm²31—-10.3 [CI -14.3; -5.8]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-11.4CI 95% -16.6 to -6.3p <0.01

Shockwave minus placebo

No adjustment reported

-18.6Equal results 02

Among completers the WOMAC total difference was −11.4 points (95% CI −16.6 to −6.3), favoring shockwaves.

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). Completers only (31 placebo, 30 shockwave); exclusion of withdrawals can bias the comparison.

WOMAC pain1 reported outcome
07
Change from baseline to 12 weeks, intent-to-treat

WOMAC pain

WOMAC pain subscale Points

means
GroupnBaselineReported change
Shockwave therapy34—-4.5 [CI -5.4; -3.6]
Placebo at 0 mJ/mm²36—-2.2 [CI -3.2; -1.2]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-2.3CI 95% -3.6 to -1p <0.01

Shockwave minus placebo

No adjustment reported

-4Equal results 00.4

WOMAC pain fell more with shockwaves: difference −2.3 points (95% CI −3.6 to −1.0).

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). The intent-to-treat columns use 36 and 34 although nine patients withdrew; imputation is not described. Per-protocol difference −2.0 (−3.4 to −0.5).

WOMAC function1 reported outcome
08
Change from baseline to 12 weeks, intent-to-treat

WOMAC function

WOMAC function subscale Points

means
GroupnBaselineReported change
Shockwave therapy34—-13.9 [CI -17.2; -10.6]
Placebo at 0 mJ/mm²36—-6 [CI -9.2; -2.8]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-7.9CI 95% -12.5 to -3.4p <0.01

Shockwave minus placebo

No adjustment reported

-14Equal results 01.5

WOMAC function improved more with shockwaves: difference −7.9 points (95% CI −12.5 to −3.4).

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). The intent-to-treat columns use 36 and 34 although nine patients withdrew; imputation is not described. Per-protocol difference −9.0 (−13.3 to −4.8). Baseline function 25.7 ± 8.9 (shockwave) versus 22.3 ± 9.4 (placebo).

WOMAC stiffness1 reported outcome
09
Change from baseline to 12 weeks, intent-to-treat

WOMAC stiffness

WOMAC stiffness subscale Points

means
GroupnBaselineReported change
Shockwave therapy34—-0.7 [CI -1; -0.4]
Placebo at 0 mJ/mm²36—-0.3 [CI -0.8; 0.2]

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Mean difference in change from baseline-0.4CI 95% -1 to 0.2p >0.05

Shockwave minus placebo

No adjustment reported

-1.1Equal results 00.3

Stiffness did not differ between groups: difference −0.4 points (95% CI −1.0 to 0.2), an interval that includes no difference.

Analysis details and source

Mean change with 95% confidence interval as printed in Table 2; negative values mean improvement. Test was an independent-samples t test or Mann–Whitney test (which one is not specified per outcome). The intent-to-treat columns use 36 and 34 although nine patients withdrew; imputation is not described. Per-protocol difference −0.4 (−1.1 to 0.3), also P>0.05. A nonsignificant difference does not show equivalence.

Patient perception of clinical severity, 5-point Likert scale1 reported outcome
10
12 weeks

Patient-rated condition

Patient perception of clinical severity, 5-point Likert scale Points (1 very poor to 5 very good)

BaselineFollow-up
Shockwave therapy
3.94
Placebo at 0 mJ/mm²
3.42
15 Points (1 very poor to 5 very good)
means
GroupnBaselineFollow-up
Shockwave therapy—3.09 (SD 0.67)3.94 (SD 0.92)
Placebo at 0 mJ/mm²—3.11 (SD 0.67)3.42 (SD 0.81)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

REPORTED COMPARISON TESTp <0.01

Shockwave versus placebo, change in patient perception at 12 weeks

Independent-samples t test or Mann–Whitney test (not specified)

Patients' rating of their knee condition rose from 3.09 to 3.94 with shockwaves and from 3.11 to 3.42 with placebo; the paper reports a better rating with shockwaves (P<0.01).

Analysis details and source

Means ± SD from the Results text; the number analysed is not stated for these values. Both the Results text and Table 2 give the changes as −0.3 and −0.9 (difference −0.6, 95% CI −0.9 to −0.2), although the reported means rose on a scale where higher is better; the sign of the change conflicts with the means. The per-protocol placebo interval (−0.3, −0.6 to −0.8) does not contain its estimate.

Participant flow1 reported outcome
11
12 weeks

Withdrawal by 12 weeks

Participant flow People

Shockwave therapy4 / 34
Placebo at 0 mJ/mm²5 / 36
REPORTED COMPARISON TESTp >0.05

Dropout rate, shockwave versus placebo

Not specified

Four of 34 shockwave and 5 of 36 placebo patients withdrew; the dropout rate did not differ (P>0.05).

Analysis details and source

Reasons: shockwave, 2 lack of efficacy and 2 work commitments (text) or lost to follow-up (Figure 1); placebo, 3 lack of efficacy and 2 increased pain with analgesic use (text) or adverse events (Figure 1).

How treatment was delivered
Device and modality

Swiss DolorClast, Electro Medical Systems (Nyon, Switzerland). Radial or focused modality not stated in the paper.

Dose per session

4,000 pulses at an energy flux density of 0.25 mJ/mm², frequency 6 Hz.

Sessions

Four sessions at weekly intervals, given by a technologist.

Target and technique

Supine, knee straight or flexed to 90°. Probe held stationary on a trigger point around the knee or at the patellofemoral and tibiofemoral borders, avoiding the peroneal nerve and vessels; aqueous coupling gel applied in circular motions.

Anesthesia and aftercare

Anesthesia not reported. No bed rest; low physical activity recommended for 48 hours. Evaluations done 1 day after treatment.

Placebo comparator

Same device, same area and manner at 0 mJ/mm²; patients could not see the device parameters. Blinding success not assessed.

Co-interventions

Patients were not offered other therapies, except the nine who withdrew.

HARMS & TOLERABILITY

The abstract states that no adverse events occurred during or after shockwave treatment, but the Discussion reports transient skin reddening after treatment and swelling for several days, without counts. In the flow chart two placebo withdrawals are labelled adverse events, while the text attributes them to increased pain and analgesic use. Systematic adverse-event collection is not described. Funded by the National Natural Science Foundation of China and the China Postdoctoral Science Foundation; the authors declare no conflict of interest.

LIMITS OF THE ANALYSIS

Author-reported: dose, intensity and frequency were not studied; parameters came from the authors' experience; long-term effects need study; no untreated group, so the authors cannot exclude the effect of placebo itself.

Extractor assessment: allocation concealment is unclear (block list, yet assignment by odd and even numbers), blinding success was not checked, the intent-to-treat analysis keeps 70 patients despite nine withdrawals without describing imputation, the test used per outcome is unspecified, and no registration is reported.

Internal inconsistencies: the Discussion says baseline pain was better with shockwaves, but Table 1 shows 7.6 in both groups; the Results text and Table 2 give negative patient-perception changes although reported means rose on a higher-is-better scale; the per-protocol placebo perception interval (−0.3, −0.6 to −0.8) excludes its estimate; the abstract reports no adverse events while the Discussion reports transient skin reddening and swelling; withdrawal reasons differ between text and Figure 1.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: dose, intensity and frequency were not studied; parameters came from the authors' experience; long-term effects need study; no untreated group, so the authors cannot exclude the effect of placebo itself.
  • Extractor assessment: allocation concealment is unclear (block list, yet assignment by odd and even numbers), blinding success was not checked, the intent-to-treat analysis keeps 70 patients despite nine withdrawals without describing imputation, the test used per outcome is unspecified, and no registration is reported.
  • Internal inconsistencies: the Discussion says baseline pain was better with shockwaves, but Table 1 shows 7.6 in both groups; the Results text and Table 2 give negative patient-perception changes although reported means rose on a higher-is-better scale; the per-protocol placebo perception interval (−0.3, −0.6 to −0.8) excludes its estimate; the abstract reports no adverse events while the Discussion reports transient skin reddening and swelling; withdrawal reasons differ between text and Figure 1.
Research review

Source-linked critical reading

Single-center, single-blinded, placebo-controlled randomized trial in China. 70 of 186 screened patients randomized, 36 placebo and 34 shockwave; 31 and 30 completed 12 weeks. Allocation concealment not described; no registration reported.

Reading depthMaterial consulted
Technical source record

Full local PDF read; All 6 PDF pages (journal pp. 661–666); Abstract; Introduction; Materials and methods; Results; Discussion; Conclusions; Table 1; Table 2; Figure 1 flow chart; Figures 2–3 captions and plots (plotted values not extracted); Acknowledgment (funding); conflict of interest statement; references

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Single-center, single-blinded, placebo-controlled randomized trial in Beijing, China (July 2011 to February 2012). Of 186 people screened, 70 were randomized: 36 to placebo and 34 to shockwaves. Five placebo and four shockwave patients withdrew; 31 and 30 completed 12 weeks. Allocation used a computer-generated block list, but the paper also describes assignment by odd and even numbers and does not describe allocation concealment. No trial registration is reported.

Participants and setting

Adults aged 45 or older from two rheumatology clinics with symptomatic primary knee osteoarthritis by American College of Rheumatology criteria, knee pain for the previous 3 months and Kellgren–Lawrence grade II or III; one target knee per person. Mean ages 61.8 (placebo) and 59.9 years (shockwave); 25 of 36 and 20 of 34 were women; 26 per group had grade II. Baseline pain on walking was 7.6 on a 10-cm VAS in both groups. Spinal stenosis, neurological disease, inflammatory or metabolic arthritis, and knee surgery or injection in the previous 6 months were exclusions.

Treatment protocol

Swiss DolorClast device (EMS, Nyon, Switzerland), applied by a technologist: 4,000 pulses at 0.25 mJ/mm² and 6 Hz per session, once a week for 4 weeks. The probe was held stationary on a trigger point around the knee or at the patellofemoral and tibiofemoral borders, avoiding the peroneal nerve and vessels, with coupling gel. Low physical activity was recommended for 48 hours. The paper does not state whether the waves were radial or focused and does not report anesthesia.

Comparison

Placebo: the same device applied to the same area in the same manner at 0 mJ/mm². Patients could not see the device settings, and a physician not involved in selection or treatment assessed outcomes. Whether patients could tell the treatments apart was not tested. No other therapies were offered, except to patients who withdrew.

What was measured

Primary: pain on movement on a 10-cm VAS (0 no pain, 10 maximal pain). Secondary: Lequesne index (maximum 24, higher worse), WOMAC (0 best to 96 worst, with pain, stiffness and function subscales) and patient perception of severity on a 5-point scale (1 very poor to 5 very good). Assessments at baseline and at 1, 4 and 12 weeks, one day after the sessions. Table 2 reports 12-week mean changes with 95% confidence intervals for the intent-to-treat and per-protocol populations.

Results and interpretation

At 12 weeks mean pain on movement fell from 7.56 to 3.83 with shockwaves and from 7.55 to 6.41 with placebo; the paper reports a greater decrease with shockwaves at 1, 4 and 12 weeks (P<0.01) but gives no between-group interval or 12-week SD for VAS. In the intent-to-treat table, differences in 12-week change versus placebo were −2.1 Lequesne points (95% CI −3.4 to −0.9), −10.6 WOMAC total points (−15.8 to −5.4), −2.3 WOMAC pain (−3.6 to −1.0) and −7.9 WOMAC function (−12.5 to −3.4), all favoring shockwaves. WOMAC stiffness did not differ (−0.4, −1.0 to 0.2). Per-protocol results were similar. Patient-rated condition rose from 3.09 to 3.94 with shockwaves and from 3.11 to 3.42 with placebo (P<0.01).

Harms and disclosures

The abstract states that no adverse events occurred during or after shockwave treatment, but the Discussion reports transient skin reddening after treatment and swelling for several days, without counts. In the flow chart two placebo withdrawals are labelled adverse events, while the text attributes them to increased pain and analgesic use. Systematic adverse-event collection is not described. Funded by the National Natural Science Foundation of China and the China Postdoctoral Science Foundation; the authors declare no conflict of interest.

Limitations

Single center, modest size and 12-week follow-up. Allocation concealment is unclear and patient blinding was not checked. Table 2 analyses all 70 patients as intent-to-treat although nine withdrew, and the handling of missing data is not described. The paper has internal inconsistencies: the Discussion says baseline pain was better with shockwaves although Table 1 shows 7.6 in both groups; the Results text and Table 2 give negative changes in patient perception although the reported mean scores rose and higher scores mean better; one per-protocol interval (−0.3, −0.6 to −0.8) does not contain its estimate; withdrawal reasons differ between the text and Figure 1. VAS values at 1 and 4 weeks appear only in Figure 2. The authors note that dose was not studied and that a no-treatment group is lacking.

Applicability

Applies to adults aged 45 or older with grade II–III knee osteoarthritis, treated with this device and dose without other therapies, over 12 weeks. It does not address grade IV arthritis, effects beyond 12 weeks, other energy levels, or comparison with exercise, medication or injections.

What stronger evidence needs

A registered multicenter trial with concealed allocation, a checked sham, prespecified handling of missing data, follow-up of at least 6 to 12 months, systematic adverse-event recording, and comparison with or addition to exercise-based care.

THE ORIGINAL SOURCE

Read the original article.

Efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a randomized controlled trial.

Zhao Z, Jing R, Shi Z, Zhao B, Ai Q, Xing G. · The Journal of surgical research · 2013

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →